Isomorphic Labs, a digital biology company specializing in advancing drug discovery through artificial intelligence (AI), has revealed a strategic research collaboration with Novartis aimed at identifying small molecule therapeutics for three undisclosed targets.
Demis Hassabis, the CEO and founder of Isomorphic Labs, highlighted the common mission to redefine medicine for improved and extended lives. The collaboration integrates Isomorphic's state-of-the-art AI and technology platform, including the latest AlphaFold model, with Novartis's expertise in creating groundbreaking medicines.
Fiona Marshall, President of Biomedical Research at Novartis, emphasized the transformative potential of advanced AI technologies like AlphaFold in reshaping drug discovery and expediting the development of life-changing medicines. The collaboration aims to leverage the unique strengths of both companies, combining AI and data science with medicinal chemistry and in-depth disease area knowledge for AI-driven drug discovery.
Operating independently within Alphabet, Isomorphic Labs focuses exclusively on applying AI to drug discovery, reimagining the drug discovery process with an AI-first approach to building predictive and generative models of biological phenomena. Isomorphic Labs has made significant progress with the Next Generation of AlphaFold, extending its capabilities to encompass small molecules and nucleic acids.
Under the collaboration agreement, Novartis will provide Isomorphic Labs with an upfront payment of $37.5 million, along with funding for specific research costs. Isomorphic Labs is poised to receive up to $1.2 billion in performance-based milestone payments, excluding the initial payment, and may also receive tiered royalties on net sales ranging from mid-single to low double digits. The collaboration signifies a joint effort to explore new frontiers in AI-driven drug discovery.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!